Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma

Published:2024-06-21 Issue:2 Volume:28 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Kim Ji¹,Kim Young²,Nam Hee-Chul¹,Kim Chang-Wook¹,Yoo Jae-Sung³,Han Ji³,Jang Jeong³,Choi Jong⁴,Yoon Seung⁴,Chun Ho Jong⁵,Oh Jung⁵,Kim Suho⁵,Lee Sung²,Sung Pil³

Affiliation:

1. Department of Gastroenterology and Hepatology, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Gyeonggi 11765, Republic of Korea

2. Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea

3. Department of Gastroenterology and Hepatology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea

4. Department of Gastroenterology and Hepatology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of KoreaJONG YOUNG CHOI

5. Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea

Publisher

Spandidos Publications

Reference41 articles.

1. Hepatocellular carcinoma;Villanueva;N Engl J Med,2019

2. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma;Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea;J Liver Cancer,2023

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

5. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?;Marisi;World J Gastroenterol,2018